10-K: electroCore 2025 10-K: Revenue Growth, CEO Transition, Going Concern

electroCore reports increased 2025 revenue driven by prescription products and general wellness offerings, alongside continued net losses and a CEO retirement, raising going concern doubts.

Summary

• Net sales increased 27% to $32.0 million in 2025, up from $25.182 million in 2024, primarily due to prescription gammaCore, Quell Fibromyalgia, and Truvaga products.
• Gross profit rose by $6.4 million to $27.8 million in 2025, with the gross margin improving to 87% from 85% in the prior year.
• The company reported a net loss of $14.0 million in 2025, an increase from $11.9 million in 2024.
• Cash used in operating activities increased to $8.2 million in 2025, compared to $6.9 million in 2024.
• As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $11.6 million, a decrease from $12.2 million at December 31, 2024.
• Management's forecasted cash is less than the requirements to fund operating expenses and capital expenditures for at least the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• Daniel S. Goldberger is retiring as Chief Executive Officer effective April 1, 2026, and Joshua S. Lev, the current CFO, will assume the role of Interim President while continuing as CFO.
• Michael Fox will join the company as Chief Operating Officer, effective April 17, 2026.
• The company launched its next-generation prescription gammaCore Emerald device in April 2025 and completed the acquisition of NeuroMetrix Inc. (NURO) on May 1, 2025, integrating the Quell platform.
• A material weakness in internal control over financial reporting related to lease accounting was identified, leading to ineffective disclosure controls as of December 31, 2025; remediation efforts are underway.
• An intellectual property lawsuit with UAB Pulsetto is ongoing, involving claims of patent and trademark infringement, false advertising, and unfair competition, with a settlement conference held on March 4, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for electroCore, marked by increasing losses and significant liquidity concerns, despite revenue growth and strategic product launches. The 'going concern' doubt and ongoing litigation weigh heavily on the outlook.

Positives

• Net sales increased 27% to $32.0 million in 2025, driven by prescription gammaCore, Quell Fibromyalgia, and Truvaga products.
• Gross profit increased by $6.4 million to $27.8 million in 2025, with the gross margin improving to 87% from 85%.
• Successfully launched the next-generation prescription gammaCore Emerald device in April 2025.
• Completed the acquisition of NeuroMetrix Inc. (NURO) on May 1, 2025, expanding product offerings with the Quell platform.
• Received FDA Breakthrough Device designation for gammaCore for PTSD treatment and Quell for chronic Chemotherapy Induced Peripheral Neuropathy (CIPN).
• Maintained strong customer relationships with the U.S. Department of Veterans Affairs (VA), which comprised 71.2% of 2025 revenue, under a contract expiring June 14, 2030.
• Continued listing of prescription gammaCore therapy in the NHS catalogue in the UK until February 2028.
• Held more than 215 patents and patent applications, including 170 issued U.S. patents, as of December 31, 2025.
• Actively engaged in remediation efforts for the identified material weakness in internal control over financial reporting, including the hiring of a new controller in September 2025.

Negatives

• Incurred significant net losses, increasing to $14.0 million in 2025 from $11.9 million in 2024.
• Cash used in operating activities increased to $8.2 million in 2025 from $6.9 million in 2024.
• Cash, cash equivalents, and marketable securities decreased to $11.6 million at December 31, 2025, from $12.2 million at December 31, 2024.
• Management's forecasted cash is less than requirements for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• A material weakness in internal control over financial reporting related to lease accounting was identified, resulting in ineffective disclosure controls as of December 31, 2025.
• An ongoing intellectual property lawsuit with UAB Pulsetto is costly, time-consuming, and could have a material adverse effect on financial position and business operations.
• Significant dependence on a limited number of customers, with the VA accounting for 71.2% of 2025 revenue, increasing concentration risk.
• Uncertainty regarding market acceptance and commercial success for newly launched products like the Quell platform and gammaCore Emerald.
• Selling, general and administrative expenses increased by $7.0 million to $38.2 million in 2025, driven by sales and marketing, legal fees, bad debt, and IT system investments.
• Risk that potentially lower pricing of direct-to-consumer cash-pay therapies could lead to lower pricing and reimbursement in legacy business channels.
• Risk of e-commerce marketplaces (e.g., Amazon) removing products if classified as medical devices requiring FDA clearance, disrupting sales channels.
• Reduced resources in research and development may delay the receipt of regulatory approvals for additional indications.

Risks

• The company may be required to obtain additional funds in the future, and these funds may not be available on acceptable terms or at all, potentially forcing a reduction or cessation of operations.
• Market acceptance and commercial success of the Quell platform and general wellness/human performance products are uncertain due to limited commercialization history and established competitors.
• Commercialization through e-commerce marketplaces presents risks including inventory management, broader competition, account suspensions, and loss of control over brand identity, with potential product removal by platforms.
• There is no assurance that the recently launched prescription gammaCore Emerald device will be well received or adopted, which may impact financial results.
• App-enabled products may require modifications and improvements, causing added expense, and undiscovered vulnerabilities could expose the company to hackers or harm its reputation.
• Sales of TAC-STIM branded products to active-duty military are subject to government budgetary cuts, shutdowns, or strikes, which could negatively impact financial results.
• Potential revenue in the United States and the United Kingdom is substantially dependent on government funding arrangements (VA, NHS), and changes in governmental policy could cause material harm.
• Unfavorable global economic conditions, geopolitical events (wars, inflation), and government regulations could adversely affect business, financial condition, or results of operations.
• Deriving a material portion of revenue from a limited number of customers (VA, NHS) creates concentration risk; the loss of one or more significant customers could adversely impact the business.
• The company has a history of significant losses and may not achieve or sustain profitability, negatively impacting financial condition and investment value.
• Challenges exist in demonstrating the medical and economic benefits of prescription products to patients, physicians, and third-party payers compared to competitors.
• Operating results may vary significantly from quarter to quarter due to seasonality, bulk orders, shipments to distributors, and other factors.
• Competition from larger, well-established companies with substantially greater resources in the chronic pain and consumer wellness markets poses a significant threat.
• International operations subject the company to operating and compliance risks, including anti-bribery laws, foreign currency fluctuations, and varied intellectual property protection.
• Inability to establish, strengthen, or protect its brands (electroCore, gammaCore, Truvaga, TAC-STIM, Quell Fibromyalgia, Quell OTC) could hinder market acceptance.
• Failure to develop and retain an effective sales force, including independent contractors, or attract additional independent contractors, may adversely impact sales efforts.
• The company may be held responsible for certain taxes or assessments and other obligations relating to the activities of its independent contractors if they are reclassified as employees.
• Reliance on third-party vendors for app development and management for app-enabled products creates significant dependency and risk of service disruption.
• Supply chains are subject to disruption, unfavorable changes to prices or terms, or quality problems from third-party contract manufacturers and suppliers, including sole-source providers.
• Outside the United States, the company relies on a single third-party distributor for the majority of its products, increasing vulnerability to distribution issues.
• The regulatory environment governing information, cybersecurity, and privacy is increasingly demanding and evolving, exposing the company to compliance risks and potential liabilities.
• Cybersecurity risks and incidents could result in compromise of confidential data, harm to customers, remediation expenses, liability under privacy laws, litigation, and reputational damage.
• An ongoing intellectual property lawsuit with UAB Pulsetto may be costly, time-consuming, and, if adversely determined, could have a material adverse effect on financial position and business operations.
• Extensive governmental regulation makes it expensive and time-consuming to bring therapies and products to market and expand indications.
• Failure to maintain regulatory approvals and clearances, or significant delays in obtaining FDA clearances, approvals, or CE Certificates of Conformity for future products, could hinder commercialization.
• The company is subject to an active FTC Consent Order, and non-compliance could lead to significant limitations or penalties.
• Failure to meet Nasdaq's continued listing standards could result in the delisting of common stock, negatively impacting market price, liquidity, and access to capital markets.
• A material weakness in internal control over financial reporting and ineffective disclosure controls could lead to inaccurate or untimely financial reporting and loss of investor confidence.
• The company does not currently intend to pay dividends, so investment return depends on stock price appreciation, which is volatile.
• Sales of a substantial number of common stock shares in the public market could cause the stock price to fall.
• The Loan and Security Agreement with Avenue requires meeting certain operating covenants and places restrictions on operating and financial flexibility, with default risks.
• As a publicly traded company, the company is subject to activist investors, which can disrupt operations and divert management attention.
• Product liability claims could result in costly litigation, significant liabilities, decreased demand, and reputational harm.
• Increases in reserves for product returns, doubtful accounts receivable, and inventory could adversely affect operating results and profitability.
• Failure to retain key executives or recruit and hire new employees could adversely affect operations and financial results.
• Price fluctuations for products and inability to reduce expenses could materially adversely affect business, results of operations, and financial condition.
• Unstable market and economic conditions, including geopolitical events, inflation, and public health crises, may have serious adverse consequences.
• Future acquisitions, strategic investments, or alliances could disrupt the business, increase capital requirements, dilute stockholders, or incur debt.
• Unanticipated costs relating to the acquisition of NeuroMetrix (NURO) could have an adverse impact on business, financial condition, and operating results.
• Regulatory requirements and changes to payors' prescription benefit plans and medical pathway plans could adversely impact business and financial results.
• The commercialization strategy of prescription devices may expose the company to increased billing, cash application, and credit risks.
• The novel approach of stimulating therapeutically relevant fibers in the vagus nerve presents significant challenges for development, commercialization, and manufacturing.
• The Quell platform, categorized as a TENS unit, requires overcoming significant challenges to successfully develop, commercialize, manufacture, and differentiate the product.
• Cost-control efforts might not assure profitability and may affect morale and make it difficult to retain or attract employees.
• Outsourcing certain finance and accounting functions increases dependence on third parties and risks of service failure.
• Failure to properly manage anticipated growth could strain resources and adversely affect commercialization and development goals.
• The status as a supplier to the federal government subjects the company to a wide variety of regulatory compliance, pricing, and contract-based requirements, with non-compliance risks.
• Changes in patent law could diminish the value of patents in general, impairing the ability to protect existing and future products and processes.
• Inability to protect the confidentiality of trade secrets could harm business and competitive position.
• Failure to identify relevant third-party patents or incorrectly interpret their relevance, scope, or expiration could adversely affect the ability to develop and market products.
• Patent terms may be inadequate to protect the competitive position for an adequate amount of time.
• Intellectual property rights do not necessarily address all potential threats to the business.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties could arise.
• Disagreements over contract interpretation in intellectual property agreements with third parties could narrow the scope of rights or affect financial obligations.
• Inability to obtain necessary intellectual property rights to future products through acquisitions and in-licenses could hinder growth.
• Reliance on open-source software, with potential non-compliance risks under various licenses.
• The increasing use, availability, and misuse of artificial intelligence (AI) present evolving risks to business, operations, cybersecurity, data protection, and regulatory compliance.
• Misuse or off-label use of gammaCore therapy may harm the company's image, result in injuries leading to product liability suits, or costly investigations and sanctions from regulatory bodies.
• Products may in the future be subject to notifications, recalls, or voluntary market withdrawals that could harm reputation, business, and financial results.
• Required reporting of certain malfunctions, deaths, and serious injuries associated with products can result in voluntary corrective actions or agency enforcement actions.
• Legislative or regulatory reforms may make it more difficult and costly to obtain regulatory clearance of product candidates and to manufacture, market, and distribute products.
• The company is subject to federal, state, and foreign healthcare laws and regulations, and a finding of failure to comply could have a material adverse effect.
• Breakthrough Designation from the FDA may not actually lead to a faster development or regulatory review or approval process and does not assure FDA approval.
• Healthcare legislative reform measures may have a material adverse effect on the company.
• ESG matters, including those related to climate change and sustainability, may have an adverse effect on business, financial condition, and operating results and may damage reputation.
• Any future U.S. federal government shutdown or any lapses in appropriations or related disruptions could materially and adversely affect sales, collections, operations, product development, and regulatory timelines.

Future Outlook

The company expects the majority of its 2026 fiscal year revenue to continue to be derived from the U.S. Department of Veterans Affairs and plans to continue utilizing the UK MedTech Funding Mandate program. It intends to make targeted investments in sales and marketing to drive commercial activities and may fund operations through existing and/or future debt and equity financings, including its at-the-market facility. However, the company's currently forecasted cash is less than the requirements to fund its planned operating expenses and capital expenditures for at least the next 12 months, which raises substantial doubt about its ability to continue as a going concern. The company is also considering a pathway for obtaining FDA clearance for gammaCore for PTSD treatment and is cooperating with investigator-initiated trials for additional indications.

Management Comments

• "We believe that our proprietary nVNS technology, which works through a variety of mechanistic pathways including the modulation of neurotransmitters, and Quell for chronic pain are designed to address many of the limitations of traditional non-invasive approaches."
• "Our goal is to be a leader in non-invasive bioelectronic technologies delivering better health."
• "We expect that the majority of 2026 fiscal year revenue will continue to come from the U.S. Department of Veterans Affairs."
• "In 2026, we plan on continuing to use this program [UK MedTech Funding Mandate]."
• "The Company believes that Pulsetto's claim is without merit and intends to defend vigorously against it and to pursue vigorously the Company's patent and non-patent counterclaims against Pulsetto."
• "Management is committed to the remediation of the material weakness."
• "Management is actively engaged in the implementation of remediation efforts... to address the material weakness."
• "The CISO regularly informs the Audit Committee and CFO of cybersecurity risks and incidents."

Industry Context

StockSavvy.ai notes that electroCore operates in the highly competitive bioelectronic technology and medical device industries, specifically targeting chronic pain (migraine, cluster headache, fibromyalgia) and general wellness/human performance. The market for migraine treatment is crowded with established pharmaceutical (triptans, CGRPs) and neuromodulation device competitors (CEFALY, Nerivio, Savi Dual), many of which are larger and more established. The chronic pain market is also dominated by medication, with TENS devices having achieved limited efficacy historically. The global wellness economy is projected to grow significantly, attracting large technology companies (Alphabet, Amazon, Apple, Samsung) with substantially greater capital and R&D resources, intensifying competition for electroCore's Truvaga and TAC-STIM products. The regulatory environment is complex and evolving, with increasing scrutiny on cybersecurity, data privacy (HIPAA, CCPA, GDPR), and AI, posing compliance challenges for the company.

Comparison to Industry Standards

• The migraine treatment market is highly competitive, with electroCore's gammaCore competing against established pharmaceutical approaches like triptans, injectables (Botox, CGRPs), and oral CGRPs, which have gained significant adoption.
• Other neuromodulation devices for migraine, such as CEFALY (sold by CEFALY Technologies sprl), Nerivio (sold by Theranica Bioelectronics), and Savi Dual (sold by eNeura, Inc.), are direct competitors, with CEFALY having an OTC clearance that could impact the competitive landscape.
• In the United Kingdom, three CGRP monoclonal antibody therapies have been recommended for use in the National Health Service by the National Institute for Health and Care Excellence for the prevention of migraine, potentially limiting gammaCore's ability to penetrate the NHS migraine market, where its current business is primarily for cluster headache.
• The Quell technology falls within the crowded transcutaneous electrical nerve stimulation (TENS) category; however, the company believes there is no direct competition to its Quell technology with the level of power, sophistication, and user-friendly features for the symptomatic relief of chronic pain.
• The global wellness economy was valued at about $6.8 trillion in 2024 and is projected to continue growing toward nearly $10 trillion by the end of 2030, attracting large technology companies like Alphabet Inc., Amazon.com, Inc., Apple Inc., and Samsung Electronics Co., Ltd., which have substantially greater capital, research and development, and sales resources than electroCore.

Management Changes

Corporate Governance

Legal Proceedings

• UAB Pulsetto v. electroCore, Inc. (Civ. No. 25-10036 (D.N.J.)): On June 11, 2025, Pulsetto filed a declaratory judgment action asserting its non-invasive vagus nerve stimulation product does not infringe electroCore's U.S. Patent No. 11,446,491. On July 16, 2025, electroCore filed counterclaims alleging infringement of multiple patents (U.S. Patent Nos. 8,948,873, 9,339,653, 10,874,857, 8,843,210, 9,242,092, 11,623,078, and 10,441,780), as well as infringement of Truvaga and gammaCore trademarks, false advertising, and unfair competition. Pulsetto requested to dismiss counterclaims on September 5, 2025. Discovery is in early stages, and a settlement conference was held on March 4, 2026. The company believes Pulsetto's claim is without merit and intends to defend vigorously and pursue counterclaims.

Related Party Transactions

• Educational grants to the Vagus Nerve Society: The company provided $150,000 in 2025 and $150,000 in 2024 for unrestricted and directed educational grants to the Vagus Nerve Society, co-founded by an executive in 2023.
• Consulting agreement with a board member: On July 11, 2024, the company entered into a consulting agreement with a board member (F. Peter Cuneo, former Chairman) for advisory services, for which $3,000 in hourly per diem fees were paid during 2025.
• Consulting agreement with a former executive: On October 4, 2024, the company entered into a consulting agreement with a former executive (Brian M. Posner) for financial and accounting consulting services, for which $4,600 in hourly fees were paid during 2025.
• License agreement with a Chinese company: On June 9, 2025, the company entered into a license agreement with a Chinese company beneficially owned by Zhang Tiyani (a beneficial owner of greater than 5% of the company's share capital), granting access to develop nVNS products in certain territories for a 10% royalty on net sales. No royalties were received in 2025.

Stakeholder Impact

• Shareholders: Face potential dilution from future equity raises, stock price volatility, risk of delisting from Nasdaq, impact from activist investors, and significant uncertainty regarding the company's ability to continue as a going concern.
• Employees: May experience lower morale and challenges in attraction/retention due to past and potential future cost reductions, including reductions in force.
• Customers (VA, NHS): Could face disruptions or delays in product availability due to supply chain issues, government shutdowns, or changes in government funding arrangements.
• Customers (Direct-to-consumer): Are exposed to risks related to e-commerce marketplace policies (e.g., product removal), brand perception, and reliance on third-party app developers for product functionality.
• Suppliers/Manufacturers: Are subject to risks of supply chain disruption, unfavorable changes to prices/terms, quality problems, and dependence on single-source suppliers.
• Creditors (Avenue): The Loan and Security Agreement is secured by a lien on substantially all company assets and contains covenants that restrict operating and financial flexibility; a default could accelerate repayment obligations.

Next Steps

• Remediate the material weakness in internal control over financial reporting, with expected completion by the end of the second quarter of 2026.
• Conduct a search for a permanent Chief Executive Officer following Daniel S. Goldberger's retirement.
• Joshua S. Lev will serve as Interim President and continue as Chief Financial Officer effective April 1, 2026.
• Michael Fox will commence as Chief Operating Officer effective April 17, 2026.
• Continue targeted investments in sales and marketing to drive commercial activities.
• Potentially relaunch the Quell OTC product in the direct-to-consumer business channel in the future.
• Continue to use the UK MedTech Funding Mandate program in 2026.
• NICE is expected to review the guidance document for gammaCore in the UK in 2026.
• British Standards Institution (BSI) is reviewing the company's technical file as part of the transition to EU MDR and UK MDR, with an updated CE certification expected upon successful completion.
• Consider a pathway for obtaining FDA clearance for gammaCore for PTSD treatment.
• Cooperate with Investigator Initiated Trials (IITs) to evaluate additional indications for products, including post-traumatic stress disorder, concussion, and anxiety.
• Continue to utilize distribution partners to commercialize nVNS technology in selected territories outside the United States and United Kingdom.
• Explore strategies to make the TAC-STIM product available to other branches of the active-duty military, first responders, elite athletes, and human performance professionals.
• Defend vigorously against the UAB Pulsetto lawsuit and pursue the company's patent and non-patent counterclaims.
• Potentially seek additional funds through borrowings or equity/debt offerings, including utilization of the at-the-market facility.
• Comply with new SEC cybersecurity disclosure rules, including periodic reporting on risk management and board oversight.
• Monitor and adapt to evolving AI technologies and related regulatory frameworks.
• Address potential UKCA marking requirements for commercialization in the UK after June 30, 2028, unless proposed amendments to the UK Medical Device Regulation are implemented.

Key Dates

Recommendation

The company faces significant financial distress, evidenced by increasing net losses, negative cash flow from operations, and a 'going concern' warning from management. While revenue growth is positive, it's insufficient to offset rising expenses and achieve profitability. The material weakness in internal controls, ongoing intellectual property litigation, and heavy reliance on government contracts introduce substantial operational and financial risks. The need for future capital raises, coupled with potential dilution and Nasdaq delisting risk, further complicates the investment thesis. A seasoned investor would likely view these factors as strong indicators of high risk and recommend selling or avoiding the stock until a clear path to sustained profitability and improved financial health is demonstrated.

Keywords

Bioelectronic technology, nVNS, gammaCore, Quell, Truvaga, TAC-STIM, Migraine, Cluster Headache, Fibromyalgia, Chronic Pain, General Wellness, Human Performance, FDA, SEC, Nasdaq, 10-K, Medical Device, Neuromodulation, Intellectual Property, Going Concern, Capital Raise, Executive Transition, Cybersecurity, Supply Chain, Government Contracts, VA, NHS